Vol 4 No 1 (2018): Current Issue
Research Article

Intraocular Pressure Control for Patients Undergoing Combination Intravitreal Anti-VEGF and Dexamethasone Therapy for Macular Edema from Retinal Vein Occlusion

Beck KD
Department of Ophthalmology, University of Texas Health San Antonio, San Antonio, Texas, United States
Tyler LD
Department of Ophthalmology, University of Texas Health San Antonio, San Antonio, Texas, United States
Iltis JM
Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, United States
Yanev YG
Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, United States
Jergensen TR
Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, United States
Woods P
Medical Center Ophthalmology Associates, San Antonio, Texas, United States
Singer J
Medical Center Ophthalmology Associates, San Antonio, Texas, United States
Bell D
Medical Center Ophthalmology Associates, San Antonio, Texas, United States
Singer MA
Medical Center Ophthalmology Associates, San Antonio, Texas, United States
Published November 29, 2018

Abstract

Background and Objective: Sustained-release dexamethasone intravitreal implant is an effective treatment for macular edema secondary to retinal vein occlusion (RVO) but ocular hypertension is a side effect. This study evaluated whether the addition of a single combination IOP-lowering medication will reliably control intraocular pressure (IOP) for those patients.  
Study Design/Patients and Methods: Retrospective chart review of 62 patients that underwent multiple injections of combination anti-VEGF and sustained-release dexamethasone intravitreal implant for macular edema secondary to RVO. IOP spikes were treated with brimonidine 0.2% - timolol 0.5%. IRB approval was obtained.  
Results: The average elevated IOP requiring treatment was 28.6 mmHg. The average IOP after adding brimonidine 0.2% - timolol 0.5% was 16.7 mmHg. 100 percent of treatment cycles had an IOP< 30 mmHg after starting treatment.   Conclusions: Using one combination IOP-lowering drop can reliably control the ocular hypertension that occurs secondary to combination therapy for macular edema in RVO.